Biomarkers Market Forecasts Positive Growth

Biomarkers may lead to a revolution in diagnostics for all categories of disease in the future according to "Biomarkers: A Market Briefing, the latest market research from Kalorama Information (Rockville, MD, USA). The report explains the types of biomarkers and their myriad diagnostic applications, and tracks current revenue and forecasts revenue for the various diagnostic segments such as cancer, epidermal growth factor receptor (EFGR) testing, and stroke diagnosis.

Personalized medicine, the use of therapies that are targeted to the individual patient, is a reality today, thanks to a growing emphasis on biomarker research. Biomarkers are anatomic, physiologic, biochemical, or molecular parameters that are associated with the presence and severity of specific diseases and illnesses. Biomarkers promise a smoother integration of diagnostics and therapeutics, and most importantly a reduction in time and cost for Phase I and II clinical trials.

Biomarkers can increase the efficiency and reduce the risks of the drug development process. New trial designs and clear guidelines for using efficacy and safety biomarkers in product development will increase the pace and reduce the cost of developing safe and effective medical products.

Worldwide, the market for biomarkers in clinical trials is expected to jump from revenues of US$427 million in 2006 to more than US$1 billion in 2010. Biomarkers: A Market Briefing discusses the major products currently marketed in each disease category as well as the important issues and trends that serious entrants into this market must take notice of Kalorama provides an accurate study of the market for biomarkers available today.



Related Links:
Kalorama Information